(ALKS) Alkermes - Ratings and Ratios
Schizophrenia, Bipolar, Alcohol, Opioid
ALKS EPS (Earnings per Share)
ALKS Revenue
Description: ALKS Alkermes
Alkermes Plc is a biopharmaceutical company that focuses on developing and commercializing treatments for various neurological disorders, including schizophrenia, bipolar I disorder, and substance dependence. The companys product portfolio includes proprietary commercial products such as ARISTADA, VIVITROL, and LYBALVI, which are used to treat these conditions.
From a business perspective, Alkermes has established collaboration agreements with major pharmaceutical companies like Janssen Pharmaceutica, leveraging its proprietary technology platforms to drive product development and commercialization. This strategic partnership enables the company to expand its reach and generate revenue through royalties and milestone payments.
To evaluate Alkermes financial performance, key performance indicators (KPIs) such as revenue growth, product sales, and operating expenses can be analyzed. For instance, the companys revenue growth rate can be assessed to determine if its increasing or decreasing. Additionally, the sales performance of its key products, such as ARISTADA and VIVITROL, can be examined to gauge their contribution to the companys overall revenue.
Other relevant KPIs for Alkermes include its research and development (R&D) expenses as a percentage of revenue, which can indicate the companys commitment to innovation and new product development. The companys gross margin can also be analyzed to assess its pricing power and ability to maintain profitability. Furthermore, Alkermes return on equity (RoE) of 25.41% suggests that the company is generating strong returns for its shareholders.
To further assess Alkermes prospects, its essential to monitor its pipeline of clinical and preclinical product candidates, as well as its commercialization efforts for existing products. By evaluating the companys progress in these areas, investors can gain insights into its potential for long-term growth and success.
ALKS Stock Overview
| Market Cap in USD | 4,952m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-07-16 |
ALKS Stock Ratings
| Growth Rating | 19.7% |
| Fundamental | 89.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -17.1% |
| Analyst Rating | 4.13 of 5 |
ALKS Dividends
Currently no dividends paidALKS Growth Ratios
| Growth Correlation 3m | -26.1% |
| Growth Correlation 12m | 2.8% |
| Growth Correlation 5y | 55% |
| CAGR 5y | 5.65% |
| CAGR/Max DD 3y | 0.18 |
| CAGR/Mean DD 3y | 0.38 |
| Sharpe Ratio 12m | 0.08 |
| Alpha | 0.24 |
| Beta | 0.267 |
| Volatility | 32.96% |
| Current Volume | 2141.6k |
| Average Volume 20d | 1658.3k |
| Stop Loss | 26.3 (-4%) |
| Signal | 1.48 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (348.4m TTM) > 0 and > 6% of Revenue (6% = 90.3m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 6.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 75.02% (prev 68.08%; Δ 6.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 521.0m > Net Income 348.4m (YES >=105%, WARN >=100%) |
| Net Debt (-448.5m) to EBITDA (450.2m) ratio: -1.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (168.4m) change vs 12m ago -1.53% (target <= -2.0% for YES) |
| Gross Margin 85.13% (prev 83.31%; Δ 1.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.51% (prev 68.33%; Δ -0.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 39.55 (EBITDA TTM 450.2m / Interest Expense TTM 10.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.85
| (A) 0.50 = (Total Current Assets 1.64b - Total Current Liabilities 506.0m) / Total Assets 2.25b |
| (B) -0.38 = Retained Earnings (Balance) -866.9m / Total Assets 2.25b |
| (C) 0.19 = EBIT TTM 421.1m / Avg Total Assets 2.23b |
| (D) -1.38 = Book Value of Equity -866.5m / Total Liabilities 628.2m |
| Total Rating: 1.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.16
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 10.51% = 5.0 |
| 3. FCF Margin 31.88% = 7.50 |
| 4. Debt/Equity 0.08 = 2.50 |
| 5. Debt/Ebitda 0.30 = 2.43 |
| 6. ROIC - WACC 15.86% = 12.50 |
| 7. RoE 23.65% = 1.97 |
| 8. Rev. Trend 29.11% = 2.18 |
| 9. EPS Trend 61.61% = 3.08 |
What is the price of ALKS shares?
Over the past week, the price has changed by -1.65%, over one month by -2.58%, over three months by -6.90% and over the past year by -1.58%.
Is Alkermes a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALKS is around 25.52 USD . This means that ALKS is currently overvalued and has a potential downside of -6.83%.
Is ALKS a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALKS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.5 | 51.5% |
| Analysts Target Price | 41.5 | 51.5% |
| ValueRay Target Price | 28.1 | 2.5% |
Last update: 2025-09-05 04:31
ALKS Fundamental Data Overview
CCE Cash And Equivalents = 521.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.4928
P/E Forward = 17.5131
P/S = 3.2899
P/B = 2.9874
P/EG = -1057.29
Beta = 0.425
Revenue TTM = 1.51b USD
EBIT TTM = 421.1m USD
EBITDA TTM = 450.2m USD
Long Term Debt = 122.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 12.9m USD (from shortTermDebt, last quarter)
Debt = 135.2m USD (Calculated: Short Term 12.9m + Long Term 122.3m)
Net Debt = -448.5m USD (from netDebt column, last quarter)
Enterprise Value = 4.57b USD (4.95b + Debt 135.2m - CCE 521.2m)
Interest Coverage Ratio = 39.55 (Ebit TTM 421.1m / Interest Expense TTM 10.6m)
FCF Yield = 10.51% (FCF TTM 479.8m / Enterprise Value 4.57b)
FCF Margin = 31.88% (FCF TTM 479.8m / Revenue TTM 1.51b)
Net Margin = 23.15% (Net Income TTM 348.4m / Revenue TTM 1.51b)
Gross Margin = 85.13% ((Revenue TTM 1.51b - Cost of Revenue TTM 223.9m) / Revenue TTM)
Tobins Q-Ratio = -5.27 (set to none) (Enterprise Value 4.57b / Book Value Of Equity -866.5m)
Interest Expense / Debt = 7.88% (Interest Expense 10.6m / Debt 135.2m)
Taxrate = 16.14% (71.6m / 443.8m)
NOPAT = 353.1m (EBIT 421.1m * (1 - 16.14%))
Current Ratio = 3.23 (Total Current Assets 1.64b / Total Current Liabilities 506.0m)
Debt / Equity = 0.08 (Debt 135.2m / last Quarter total Stockholder Equity 1.62b)
Debt / EBITDA = 0.30 (Net Debt -448.5m / EBITDA 450.2m)
Debt / FCF = 0.28 (Debt 135.2m / FCF TTM 479.8m)
Total Stockholder Equity = 1.47b (last 4 quarters mean)
RoA = 15.47% (Net Income 348.4m, Total Assets 2.25b )
RoE = 23.65% (Net Income TTM 348.4m / Total Stockholder Equity 1.47b)
RoCE = 26.39% (Ebit 421.1m / (Equity 1.47b + L.T.Debt 122.3m))
RoIC = 22.85% (NOPAT 353.1m / Invested Capital 1.55b)
WACC = 6.99% (E(4.95b)/V(5.09b) * Re(7.0%)) + (D(135.2m)/V(5.09b) * Rd(7.88%) * (1-Tc(0.16)))
Shares Correlation 3-Years: 18.18 | Cagr: 0.22%
Discount Rate = 7.0% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.74% ; FCFE base≈418.8m ; Y1≈491.5m ; Y5≈747.4m
Fair Price DCF = 77.66 (DCF Value 12.82b / Shares Outstanding 165.1m; 5y FCF grow 18.48% → 3.0% )
EPS Correlation: 61.61 | EPS CAGR: 260.5% | SUE: 1.63 | # QB: True
Revenue Correlation: 29.11 | Revenue CAGR: 17.22%
Additional Sources for ALKS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle